Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Carboplatin adaptive therapy improves treatment efficacy without increasing daily dose due to reduced fitness of drug-resistant populations, which can be tracked using cfDNA and could direct adaptive therapy in future clinical trials. See related commentary by Gatenby, p. 3373.
Authors
- Mohammed A. Khan (ORCID: https://orcid.org/0000-0001-9473-8679)
- Michelle Lockley (ORCID: https://orcid.org/0000-0002-9281-5789)
- Trevor A. Graham (ORCID: https://orcid.org/0000-0001-9582-1597)
- Ann‐Marie Baker (ORCID: https://orcid.org/0000-0001-8905-9137)
- Kane Smith (ORCID: https://orcid.org/0000-0002-8661-7401)
- Eszter Lakatos (ORCID: https://orcid.org/0000-0002-7221-6850)
- Maximilian Mossner (ORCID: https://orcid.org/0000-0001-9751-3803)
- Helen Hockings (ORCID: https://orcid.org/0000-0003-4509-6387)
- Jacqueline McDermott (ORCID: https://orcid.org/0000-0001-8052-7133)
- Weini Huang (ORCID: https://orcid.org/0000-0002-9016-2665)
- Nikolina Bakali
Institutions
- Institute of Cancer Research (GB)
- Imperial College Healthcare NHS Trust (GB)
- Queen Mary University of London (GB)
- Barts Health NHS Trust (GB)
- Chalmers University of Technology (SE)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1158/0008-5472.can-25-0351
- Citations
- 13
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 12.17
Funders
- Eli Lilly and Company
- Wellcome Trust
- Barts Charity
- Cancer Research UK
- National Institutes of Health
- National Cancer Institute